La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

MiMedx Group Performance dei guadagni passati

Il passato criteri di controllo 5/6

MiMedx Group ha registrato una crescita degli utili a un tasso medio annuo di 52.2%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 19.1%. I ricavi sono stati in crescita a un tasso medio annuo di 1.9%. Il ritorno sul capitale proprio di MiMedx Group è 51.7% e ha margini netti di 23.1%.

Informazioni chiave

52.2%

Tasso di crescita degli utili

51.2%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	1.9%
Rendimento del capitale proprio	51.7%
Margine netto	23.1%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

Ripartizione dei ricavi e delle spese

Come MiMedx Group guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqCM:MDXG Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	340	79	209	11
31 Mar 24	335	68	216	12
31 Dec 23	321	56	216	13
30 Sep 23	309	19	215	6
30 Jun 23	295	2	219	8
31 Mar 23	281	-18	225	10
31 Dec 22	268	-27	221	13
30 Sep 22	261	-34	216	22
30 Jun 22	256	-28	209	20
31 Mar 22	258	-19	202	19
31 Dec 21	242	-18	199	10
30 Sep 21	260	-35	223	16
30 Jun 21	261	-83	233	15
31 Mar 21	246	-88	231	13
31 Dec 20	248	-83	240	12
30 Sep 20	256	-73	212	11
30 Jun 20	281	-8	210	10
31 Mar 20	294	-17	233	11
31 Dec 19	299	-26	265	11
30 Sep 19	315	-54	270	13
30 Jun 19	314	-67	287	14
31 Mar 19	342	-48	295	15
31 Dec 18	359	-30	295	16
30 Sep 18	354	41	275	15
30 Jun 18	352	59	260	16
31 Mar 18	333	65	235	17
31 Dec 17	321	65	220	18
30 Sep 17	303	35	216	18
30 Jun 17	283	21	205	15
31 Mar 17	264	15	192	14
31 Dec 16	222	0	172	14
30 Sep 16	227	20	168	11
30 Jun 16	212	23	154	10
31 Mar 16	200	27	144	9
31 Dec 15	187	29	133	8
30 Sep 15	175	20	126	8
30 Jun 15	160	17	115	8
31 Mar 15	139	11	104	7
31 Dec 14	118	6	90	7
30 Sep 14	97	1	75	7
30 Jun 14	79	-3	64	6
31 Mar 14	67	-3	54	5
31 Dec 13	59	-4	46	5
30 Sep 13	52	-4	40	5

Guadagni di qualità: MDXG ha un livello elevato di guadagni non monetari.

Margine di profitto in crescita: Gli attuali margini di profitto netti di MDXG (23.1%) MDXG sono più alti rispetto allo scorso anno (0.7%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: MDXG è diventata redditizia negli ultimi 5 anni, aumentando i guadagni del 52.2% all'anno.

Accelerare la crescita: La crescita degli utili di MDXG nell'ultimo anno ( 3958.9% ) supera la media quinquennale ( 52.2% all'anno).

Guadagni vs Settore: La crescita degli utili MDXG nell'ultimo anno ( 3958.9% ) ha superato la percentuale del settore Biotechs 0.5%.

MiMedx Group Performance dei guadagni passati

Il passato criteri di controllo 5/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

MiMedx Group, Inc. to Report Q2, 2024 Results on Jul 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Recent updates

Consensus EPS estimates fall by 10%

New major risk - Revenue and earnings growth

MiMedx Group, Inc. Provides Sales Guidance for the Full Year of 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

MiMedx Group, Inc. Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature- Scientific Reports

MiMedx Group, Inc. to Report Q2, 2024 Results on Jul 31, 2024

MiMedx Group, Inc. Announces the Appointment of Kim Moller to Chief Commercial Officer

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Insider recently sold US$162k worth of stock

Mimedx Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Insider selling

Insider recently sold US$250k worth of stock

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Mimedx Group, Inc. Announces Launch of Epieffect

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 loss in 2Q 2022)

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Consensus EPS estimates upgraded to US$0.10 loss

Price target decreased by 9.3% to US$9.29

Insider recently sold US$84k worth of stock

Insider notifies of intention to sell stock

MiMedx Group, Inc., Annual General Meeting, Jun 13, 2023

Insider recently sold US$276k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Insider notifies of intention to sell stock

Chief Financial Officer recently sold US$85k worth of stock

Chief Financial Officer notifies of intention to sell stock

MiMedx Group, Inc. Announces Chief Executive Officer Changes

MiMedx Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Price target decreased to US$10.25

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Net Sales Guidance for the Fourth Quarter and Full Year 2022

MiMedx Group, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Price target decreased to US$10.25

Mimedx Group, Inc. Announces Management Changes

High number of new directors

MiMedx Group, Inc. Announces Launch of AXIOFILL

MiMedx Group, Inc. Announces Launch of AMNIOEFFECT™

Insider recently sold US$94k worth of stock

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Consensus EPS estimates fall by 12%

MiMedx Group, Inc. Provides Sales Guidance for the Year Ending December 31, 2022

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range